June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A Reproducible in Vitro Assay to Measure Immunomodulatory Properties of Mesenchymal Stem Cell on the Corneal Epithelial Cells
Author Affiliations & Notes
  • Medi Eslani
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL
  • Judy Hamouie
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL
  • Hongyu Ying
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL
  • Peiman Hematti
    Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
  • Ali R Djalilian
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL
  • Footnotes
    Commercial Relationships Medi Eslani, None; Judy Hamouie, None; Hongyu Ying, None; Peiman Hematti, None; Ali Djalilian, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 705. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Medi Eslani, Judy Hamouie, Hongyu Ying, Peiman Hematti, Ali R Djalilian; A Reproducible in Vitro Assay to Measure Immunomodulatory Properties of Mesenchymal Stem Cell on the Corneal Epithelial Cells. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):705.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The anti-inflammatory effects of mesenchymal stem cells (MSCs) have been recognized as one of their major modes of action and the basis for their utilization in a number of human clinical trials. However, there is no well-established reproducible in vitro assay to evaluate the effect of MSCs on inflammation of human corneal epithelial cells (HCEC). Activation of Toll-like receptor 3 (TLR3) in HCECs results in significant induction of cytokines and chemokine. We developed a reproducible in vitro assay, based on TLR3 activation, to evaluate the immunomodulatory effects of MSC derived conditioned media (CM) on HCECs.

Methods: MSCs were harvested from the human bone marrow and cultured in serum containing media. Serum-free conditioned media were collected from them at 80% to 90% confluency. Growth factor-starved telomerase-immortalized HCEC were treated with ​polyinosinic-polycytidylic acid (poly I:C) for 30 minutes (to activate TLR3) then washed and exposed to either conditioned media or basic medium for 6 hours. The mRNA expression of selected cytokines was determined by real-time qPCR.

Results: The optimal concentration of poly I:C for this assay was determined to be 1 µg/ml. Of downstream TLR3 related cytokines and chemokines, IL-6, TNF- α and CCL5/RANTES demonstrated better consistency. TLR3 activation of HCECs resulted in 2.7 ± 1.1, 3.2 ± 0.9 and 27.6 ± 7.6 fold increase in IL-6, TNF-α and CCL5 compared to control, respectively (P < 0.001). BM-MSC derived CM significantly decreased inflammatory cytokine release to 1.3 ± 0.8, 1.7 ± 1.4 and 11.6 ± 5.3 fold change, respectively (P value for each comparison < 0.01). CM from low passage (passage number ≤4) BM-MSC had slightly more anti-inflammatory effect compared to high passage (passage number ≥ 8), both from one donor (P < 0.05).

Conclusions: We have developed a reproducible in vitro assay to evaluate the immunomodulatory properties of MSC-derived CM on HCECs. Based on this assay, low passage BM-MSC derived CM demonstrated significant anti-inflammatory effects in corneal epithelial cells.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×